There are about 11304 clinical studies being (or have been) conducted in Denmark. The country of the clinical trial is determined by the location of where the clinical research is being studied. Most studies are often held in multiple locations & countries.
The purpose of this study was to study the use of a Core Questionnaire that included several questions from each PBRN (DPBRN, PEARL, PRECEDENT - collectively know as CONDOR) that had been extracted from questionnaires previously administered as part of their initial research program activities. This protocol was the first administration of this core questionnaire with the purpose of assessing dental practice changes that may have occured since the earlier administration of the individual questions with the separate networks.It also collected baseline data for others.
The principal goal of this study was to assess the feasibility of plasma glucose testing in private dental practice. A second aim was was to assess prevalence of plasma glucose abnormalities in dental patients seen by (DPBRN) practitioner-investigators.
The purpose of this study was to investigate the process involved when making decisions about the diagnosis and treatment of questionable lesions, as well as determine if there is any association between lesions progression (or depth, if opened) and clinical characteristics and baseline risk assessment.
The purpose of this study was to administer two questionnaires. The first, a Dental Satisfaction Questionnaire to assess patient satisfaction with a restoration visit using patients recruited from practices participating in the Dental PBRN "Reasons for replacement or repair of dental restorations" study. The second questionnaire (completed by the practitioner) was a brief single page questionnaire to evaluate the patient visit.
The purpose of this study is to assess the quality and expected lifespan of fillings recorded in the DPBRN "Reasons for placing the first restoration on permanent tooth surfaces" study, and the factors affecting how long the fillings last.
The purpose of this study is to assess the quality and expected lifespan of fillings recorded in the DPBRN "Reasons for replacement and repair of dental restorations" study, and the factors affecting how long the fillings last.
The purpose of this study was to collect long-term safety and tolerability, long-term efficacy, and health outcome data in all patients currently ongoing in the fingolimod multiple sclerosis clinical development program. This study combined all currently ongoing Phase II and III fingolimod extension studies as well as ongoing and newly planned studies into one single long-term extension protocol that provided patients with continuous treatment until fingolimod was registered, commercially available, and reimbursed in the respective countries.
This two-stage, multi-center, randomized, controlled, open-label study will investigate the pharmacokinetics, efficacy and safety of rituximab SC versus rituximab IV in participants with previously untreated follicular non-Hodgkin's lymphoma. Participants will be randomized to receive 375 milligrams per meter square (mg/m^2) rituximab as IV infusion or 1400 milligrams (mg) rituximab SC. In addition, participants will receive standard chemotherapy. Participants who achieved a complete or partial response (PR) after 8 treatment cycles, will receive maintenance treatment for a further maximum number of 12 cycles. Maintenance treatment cycles will be repeated every 8 weeks. This is a two-stage study. Stage 1 was designed to confirm the chosen rituximab SC dose resulting in comparable rituximab serum Ctrough levels compared with rituximab IV, when given as part of induction treatment every 3 weeks. Enrollment for Stage 2 started after the rituximab SC dose was established in Stage 1. Stage 2 aimed to further investigate the efficacy and safety of rituximab SC compared with rituximab IV. The anticipated time on study treatment is 96 weeks.
A study to investigate the analgesic efficacy of AZD2423 compared with placebo after 28 days treatment in patients with posttraumatic neuralgia.
PF-00489791 is an inhibitor of phosphodiesterase type 5. Our hypothesis is that PF-00489791 will enhance the relaxation of blood vessels within the kidney and so reduce blood pressure, improving renal function.